Menu

Explainer

Health screening tests by age: what adults need and when

Screening tests look for a disease before it causes symptoms. The US Preventive Services Task Force (USPSTF) decides which ones are worth it, for whom and from what age. Here they are in one place, each with a check that applies the rule to you.

Last reviewed: By the uncovermyrisk.com editorial team Educational only, not medical advice.

This page lists screenings for adults without symptoms. If you have symptoms, a family history that changes the plan, or a known condition, the tests you need are a diagnosis question for your doctor, not screening. Educational only, not medical advice.

The checklist

ScreeningWho (USPSTF)How oftenCheck
DepressionAll adults, including pregnant and postpartum people and adults 65 and older (B) (USPSTF 2023)No best interval establishedPHQ-9 check
Heart-healthy diet and activityAdults with high blood pressure, dyslipidemia or multiple risk factors: offer or refer to counseling (B) (USPSTF 2020); adults without risk factors: individualized (C) (USPSTF 2022)Programs usually 6 to 18 monthsLifestyle counseling check
WeightAdults with a BMI of 30 or higher: offer or refer to an intensive behavioral program (B) (USPSTF 2018)Program usually 1 to 2 yearsWeight program check
Tobacco useAll adults, including pregnant people: ask, advise quitting and offer help (A) (USPSTF 2021)No interval givenQuit smoking check
Unhealthy drug useAll adults 18 or older, by asking questions (B) (USPSTF 2020)Little evidence on how oftenDrug use check
Intimate partner violenceWomen of reproductive age, including pregnant and postpartum women (B) (USPSTF 2025)No evidence on how oftenPartner violence check
Sun protectionFair-skinned people aged 6 months to 24 years: counseling to reduce UV exposure (B); fair-skinned adults over 24: offered selectively (C) (USPSTF 2018)No interval givenSkin cancer prevention check
Skin cancer (skin exam)Adolescents and adults without signs, symptoms or a history of skin cancer: evidence insufficient (I) (USPSTF 2023)No interval givenSkin exam check
Oral (mouth) cancerAdults without symptoms, mouth exam in primary care: evidence insufficient (I) (USPSTF 2013)No interval givenOral cancer check
Vitamin D and calciumPostmenopausal women: against daily 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures (D); evidence insufficient for higher doses, men and premenopausal women (I) (USPSTF 2018)No interval givenVitamin D check
Vitamin D deficiencyAdults without symptoms living in the community, not pregnant: evidence insufficient to weigh testing (I) (USPSTF 2021)No interval givenVitamin D level check
Menopausal hormone therapyPostmenopausal people: against combined estrogen and progestin, or estrogen alone after hysterectomy, to prevent chronic conditions (D) (USPSTF 2022)Not recommended for preventionHormone therapy check
Weight gain in pregnancyPregnant adolescents and adults: offer counseling for healthy weight gain (B) (USPSTF 2021)During pregnancyPregnancy weight gain calculator
Folic acidEveryone who is planning to or could become pregnant: 0.4 to 0.8 mg daily (A) (USPSTF 2023)Daily, from 1 month before conception through the first 2 to 3 monthsFolic acid check
Perinatal depression preventionPregnant and postpartum people at increased risk: counseling (B) (USPSTF 2019)During pregnancy and up to 1 year after birthRisk factors
AnxietyAdults 64 and younger, including pregnant and postpartum people (B); evidence insufficient at 65 and older (I) (USPSTF 2023)No evidence on how oftenGAD-7 check
Eating disordersTeens and adults 10 and older without signs or symptoms: evidence insufficient (I) (USPSTF 2022)No interval givenEating disorder check
ScoliosisChildren and teens 10 to 18 without symptoms: evidence insufficient (I) (USPSTF 2018)No interval givenScoliosis check
Blood leadChildren enrolled in Medicaid: required test (CDC); other children: testing focused on those at high risk (CDC)Medicaid: 12 and 24 months, or 24 to 72 months if never testedBlood lead check
Cholesterol (children)Children and teens 20 or younger without symptoms: evidence insufficient (I) (USPSTF 2023)No interval givenChild cholesterol check
Blood pressure (children)Children and teens 3 to 18 not known to have high blood pressure: evidence insufficient (I) (USPSTF 2020)No good evidence on how oftenChild blood pressure check
Tooth decay (under 5)Fluoride varnish from the first tooth (B); fluoride supplements from 6 months if water is low in fluoride (B); routine screening exam in primary care: evidence insufficient (I) (USPSTF 2021)Varnish most often every 6 months in studiesTooth decay prevention check
Diabetes (children)Children and teens under 18 without symptoms: evidence insufficient (I) (USPSTF 2022)No interval givenChild diabetes check
High BMI (children)Children and teens 6 and older at or above the 95th BMI percentile: intensive behavioral program (B) (USPSTF 2024)26 or more contact hoursChild high BMI check
Speech and language delayChildren 5 and younger with no concerns: evidence insufficient (I) (USPSTF 2024)No interval givenSpeech and language check
Anxiety (children)Children and teens 8 to 18 (B); 7 and younger: evidence insufficient (I) (USPSTF 2022)No good evidence on how oftenChild anxiety check
Depression (teens)Adolescents 12 to 18 (B); 11 and younger: evidence insufficient (I) (USPSTF 2022)No good evidence on how oftenTeen depression check
Blood pressureAll adults 18 and older (A) (USPSTF 2021)Yearly from 40 or at higher risk; every 3 to 5 years at 18 to 39 if normalHow often check
Hepatitis CAll adults 18 to 79 (B) (USPSTF 2020)Once for most; again with ongoing riskHepatitis C check
Gestational diabetesPregnant people at 24 weeks or later (B); evidence insufficient before 24 weeks (I) (USPSTF 2021)Once per pregnancy, usually 24 to 28 weeksGlucose test timing
HIVEveryone 15 to 65, all pregnancies (A) (USPSTF 2019)At least once; repeat at increased riskHIV check
HIV PrEPAdolescents and adults at increased risk of HIV, 35 kg or more: prescribe PrEP (A) (USPSTF 2023)While at increased risk; HIV test every 2 to 3 monthsPrEP check
Chlamydia and gonorrheaSexually active women 24 or younger, and 25 or older at increased risk (B); evidence insufficient for men (I) (USPSTF 2021)Again with new or ongoing risk since the last negative testChlamydia and gonorrhea check
Latent tuberculosisAdults at increased risk, such as people born in countries where TB is common or who lived in shelters or prisons (B) (USPSTF 2023)Once to yearly, depending on ongoing riskLatent TB check
SyphilisTeens and adults at increased risk (A) (USPSTF 2022); all pregnancies, as early as possible (A) (USPSTF 2025)Not well established; at least yearly with ongoing high riskSyphilis check
Genital herpesTeens and adults without symptoms, including pregnant people: do not routinely screen with a blood test (D) (USPSTF 2023)Not recommendedGenital herpes check
High blood pressure in pregnancyAll pregnant people without known high blood pressure (B) (USPSTF 2023)Every prenatal visitCheck a reading
Hepatitis BTeens and adults at increased risk (B), all pregnancies (A) (USPSTF 2020)Once; again with ongoing risk if not vaccinatedHepatitis B check
Cervical cancerWomen 21 to 65 (A) (USPSTF 2018)Pap every 3 years; from 30, HPV test or cotest every 5 years is an optionCervical check
Diabetes and prediabetesAdults 35 to 70 with overweight or obesity (B) (USPSTF 2021)Every 3 years may be reasonable after a normal resultDiabetes testing check
Breast cancerWomen 40 to 74 (B) (USPSTF 2024)Mammogram every other yearBreast check
BRCA gene riskWomen with a personal or family history of breast, ovarian, tubal or peritoneal cancer, or linked ancestry: brief family risk tool (B); not routine for others (D) (USPSTF 2019)Once, then counseling if positive7-question check
Ovarian cancerWomen without symptoms and no known high-risk hereditary syndrome: do not screen (D) (USPSTF 2018)Not recommendedOvarian cancer check
Thyroid cancerAdults without symptoms: do not screen by neck exam or ultrasound (D) (USPSTF 2017)Not recommendedThyroid cancer check
Pancreatic cancerAdults without symptoms, not known to be at high risk: do not screen (D) (USPSTF 2019)Not recommendedPancreatic cancer check
Testicular cancerAdolescent and adult males without symptoms: do not screen by clinician exam or self-exam (D) (USPSTF 2011)Not recommendedTesticular cancer check
Bladder cancerAdults without symptoms: evidence insufficient (I) (USPSTF 2011)No interval givenBladder check
Bacterial vaginosis in pregnancyPregnant, no symptoms, not at increased preterm risk: do not screen (D); at increased risk: evidence insufficient (I) (USPSTF 2020)Not recommendedBV in pregnancy check
Iron deficiency in pregnancyPregnant, no symptoms: evidence insufficient for screening and for routine iron supplements (I) (USPSTF 2024)No interval givenIron in pregnancy check
Asymptomatic bacteriuriaPregnant: urine culture at the first prenatal visit or 12 to 16 weeks (B); nonpregnant adults: do not screen (D) (USPSTF 2019)Once, early in pregnancyBacteriuria check
Hearing lossAdults 50+ who have not noticed a hearing problem: evidence insufficient (I) (USPSTF 2021)No interval givenHearing loss check
Vision (visual acuity)Adults 65+ who have not noticed a vision problem: evidence insufficient (I) (USPSTF 2022)No interval givenVision check
GlaucomaAdults 40+ without signs or symptoms: evidence insufficient (I) (USPSTF 2022)No interval givenGlaucoma check
Cognitive impairmentAdults 65+ living in the community, no recognized signs: evidence insufficient (I) (USPSTF 2020)No interval givenMemory check
Breast cancer prevention medicinesWomen 35 or older at increased risk and low risk of side effects: offer tamoxifen, raloxifene or an aromatase inhibitor (B); not routine for others (D) (USPSTF 2019)Recheck when risk factors changeMedicine check
Colorectal cancerAdults 45 to 75 (50 to 75: A; 45 to 49: B); selectively 76 to 85 (C) (USPSTF 2021)Depends on the test: yearly stool test up to colonoscopy every 10 yearsColon check
Lung cancerAdults 50 to 80 with 20 or more pack-years who smoke or quit within 15 years (B) (USPSTF 2021)Low-dose CT every yearLung check
Prostate cancerMen 55 to 69: a personal decision (C); not from 70 (D) (USPSTF 2018)Decided with your doctorProstate check
OsteoporosisWomen 65 and older; younger postmenopausal women at higher risk (B) (USPSTF 2025)Bone density (DXA) scan; repeat timing set with your doctorOsteoporosis check
Abdominal aortic aneurysmMen 65 to 75 who ever smoked (B) (USPSTF 2019)One ultrasound, onceAAA check
Atrial fibrillationAdults 50 or older without symptoms: evidence insufficient (I) (USPSTF 2022)No interval givenAFib check
ECG for heart riskAdults without symptoms: low risk, do not screen (D); intermediate or high risk, evidence insufficient (I) (USPSTF 2018)Not recommended at low riskECG check
Carotid artery narrowingAdults without symptoms, stroke or TIA: do not screen (D) (USPSTF 2021)Not recommendedCarotid check
Peripheral artery disease (ABI)Adults without symptoms or known PAD/CVD: evidence insufficient (I) (USPSTF 2018)No interval givenPAD check
Celiac diseaseAny age without signs or symptoms: evidence insufficient (I) (USPSTF 2017)No interval givenCeliac check
COPDAdults without breathing symptoms: do not screen (D) (USPSTF 2022)Not recommendedCOPD check

The letters in brackets are the USPSTF grade for each recommendation. Each check explains its grade and what it means for you.

By age

18 to 39

Blood pressure every 3 to 5 years if normal and not at higher risk (USPSTF 2021). A one-time hepatitis C test (USPSTF 2020) and at least one HIV test (USPSTF 2019). Women: cervical screening from 21 (USPSTF 2018). Hepatitis B if a risk factor applies (USPSTF 2020). From 35, a diabetes test if you have overweight or obesity (USPSTF 2021).

40 to 49

Blood pressure every year (USPSTF 2021). Women: mammograms every other year from 40 (USPSTF 2024). Colorectal screening from 45 (USPSTF 2021). The earlier tests continue.

50 to 64

Lung cancer screening from 50 if your smoking history qualifies (USPSTF 2021). Men: from 55, talk about a PSA test (USPSTF 2018). Postmenopausal women at higher risk: a bone density scan (USPSTF 2025).

65 and older

Women: a bone density scan (USPSTF 2025). Women can stop cervical screening after 65 if earlier screening was adequate and they are not at higher risk (USPSTF 2018). Men 65 to 75 who ever smoked: one aneurysm ultrasound (USPSTF 2019). Colorectal screening through 75, then a choice to 85 (USPSTF 2021). Mammograms through 74 (USPSTF 2024). No routine PSA test from 70 (USPSTF 2018).

Other guidelines

Other groups sometimes recommend more. The CDC advises every adult to be tested for hepatitis B at least once (CDC 2023) and for hepatitis C at least once with no upper age limit (CDC 2020), and the American Diabetes Association advises testing everyone from 35 (ADA Standards 2026). The American Cancer Society has its own schedules for breast (ACS), cervical (ACS 2025), colorectal (ACS), lung (ACS 2023) and prostate cancer (ACS). Each check on this site shows where these differ from the USPSTF.

Also see which numbers you need for each tool and the heart risk calculator. To build a list for your own age and sex, our sister site knowtoprevail.com puts the USPSTF grade A and B screenings in one plan.

Sources

  1. US Preventive Services Task Force. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2021;325(16):1650-1656. www.uspreventiveservicestaskforce.org/uspstf/recommendation/hypertension-in-adults-screening
  2. US Preventive Services Task Force. Screening for Prediabetes and Type 2 Diabetes: Recommendation Statement. JAMA. 2021;326(8):736-743. www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes
  3. US Preventive Services Task Force. Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323(10):970-975. www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening
  4. US Preventive Services Task Force. Screening for Hepatitis B Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;324(23):2415-2422. www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-b-virus-infection-screening
  5. US Preventive Services Task Force. Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;321(23):2326. www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening
  6. US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening
  7. US Preventive Services Task Force. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22):1918-1930. www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
  8. US Preventive Services Task Force. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(7):674-686. www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening
  9. US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962-970. www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
  10. US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901-1913. www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening
  11. US Preventive Services Task Force. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 2025;333(6):498-508. www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening
  12. US Preventive Services Task Force. Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322(22):2211-2218. www.uspreventiveservicestaskforce.org/uspstf/recommendation/abdominal-aortic-aneurysm-screening
  13. Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations, United States, 2023. MMWR Recomm Rep. 2023;72(No. RR-1):1-25. doi.org/10.15585/mmwr.rr7201a1
  14. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for Hepatitis C Screening Among Adults, United States, 2020. MMWR Recomm Rep. 2020;69(No. RR-2):1-17. doi.org/10.15585/mmwr.rr6902a1
  15. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes 2026. Diabetes Care. 2026;49(Suppl 1):S27-S49. doi.org/10.2337/dc26-S002
  16. American Cancer Society. American Cancer Society Recommendations for the Early Detection of Breast Cancer. www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html
  17. Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;76(1):e70041. doi.org/10.3322/caac.70041
  18. American Cancer Society. American Cancer Society Guideline for Colorectal Cancer Screening. www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html
  19. Wolf AMD, Oeffinger KC, Shih TY, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024;74(1):50-81. doi.org/10.3322/caac.21811
  20. American Cancer Society. American Cancer Society Recommendations for Prostate Cancer Early Detection. www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html
  21. US Preventive Services Task Force. Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(23):2057. www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-adults
  22. US Preventive Services Task Force. Screening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(24):2163. www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening
  23. US Preventive Services Task Force. Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(6):531. www.uspreventiveservicestaskforce.org/uspstf/recommendation/gestational-diabetes-screening
  24. US Preventive Services Task Force. Screening for Chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(10):949. www.uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydia-and-gonorrhea-screening
  25. US Preventive Services Task Force. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(17):1487. www.uspreventiveservicestaskforce.org/uspstf/recommendation/latent-tuberculosis-infection-screening
  26. US Preventive Services Task Force. Screening for Syphilis Infection in Nonpregnant Adolescents and Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2022;328(12):1243. www.uspreventiveservicestaskforce.org/uspstf/recommendation/syphilis-infection-nonpregnant-adults-adolescents-screening
  27. US Preventive Services Task Force. Screening for Syphilis Infection During Pregnancy: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2025;333(22):2006. www.uspreventiveservicestaskforce.org/uspstf/recommendation/syphilis-infection-in-pregnancy-screening
  28. US Preventive Services Task Force. Screening for Hypertensive Disorders of Pregnancy: US Preventive Services Task Force Final Recommendation Statement. JAMA. 2023;330(11):1074. www.uspreventiveservicestaskforce.org/uspstf/recommendation/hypertensive-disorders-pregnancy-screening
  29. US Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322(7):652. www.uspreventiveservicestaskforce.org/uspstf/recommendation/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing
  30. US Preventive Services Task Force. Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;321(6):580. www.uspreventiveservicestaskforce.org/uspstf/recommendation/perinatal-depression-preventive-interventions
  31. US Preventive Services Task Force. Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323(22):2301. www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening
  32. US Preventive Services Task Force. Screening for Intimate Partner Violence and Caregiver Abuse of Older or Vulnerable Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2025;334(4):329. www.uspreventiveservicestaskforce.org/uspstf/recommendation/intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-screening
  33. US Preventive Services Task Force. Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(3):265. www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions
  34. US Preventive Services Task Force. Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2023;330(5):454. www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication
  35. US Preventive Services Task Force. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(11):1163. www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions
  36. US Preventive Services Task Force. Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(11):1134. www.uspreventiveservicestaskforce.org/uspstf/recommendation/skin-cancer-counseling
  37. US Preventive Services Task Force. Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;324(20):2069. www.uspreventiveservicestaskforce.org/uspstf/recommendation/healthy-diet-and-physical-activity-counseling-adults-with-high-risk-of-cvd
  38. US Preventive Services Task Force. Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(4):367. www.uspreventiveservicestaskforce.org/uspstf/recommendation/healthy-lifestyle-and-physical-activity-for-cvd-prevention-adults-without-known-risk-factors-behavioral-counseling
  39. US Preventive Services Task Force. Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(15):1592. www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-d-calcium-or-combined-supplementation-for-the-primary-prevention-of-fractures-in-adults-preventive-medication
  40. US Preventive Services Task Force. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(17):1740. www.uspreventiveservicestaskforce.org/uspstf/recommendation/menopausal-hormone-therapy-preventive-medication
  41. US Preventive Services Task Force. Behavioral Counseling Interventions for Healthy Weight and Weight Gain in Pregnancy: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(20):2087. www.uspreventiveservicestaskforce.org/uspstf/recommendation/healthy-weight-and-weight-gain-during-pregnancy-behavioral-counseling-interventions
  42. US Preventive Services Task Force. Preexposure Prophylaxis to Prevent Acquisition of HIV: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;330(8):736. www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis
  43. US Preventive Services Task Force. Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(4):360. www.uspreventiveservicestaskforce.org/uspstf/recommendation/atrial-fibrillation-screening
  44. US Preventive Services Task Force. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322(9):857-867. www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction
  45. US Preventive Services Task Force. Screening for Asymptomatic Carotid Artery Stenosis: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2021;325(5):476-481. www.uspreventiveservicestaskforce.org/uspstf/recommendation/carotid-artery-stenosis-screening
  46. US Preventive Services Task Force. Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2022;327(18):1806-1811. www.uspreventiveservicestaskforce.org/uspstf/recommendation/chronic-obstructive-pulmonary-disease-screening
  47. US Preventive Services Task Force. Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(6):588-594. www.uspreventiveservicestaskforce.org/uspstf/recommendation/ovarian-cancer-screening
  48. US Preventive Services Task Force. Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2017;317(18):1882-1887. www.uspreventiveservicestaskforce.org/uspstf/recommendation/thyroid-cancer-screening
  49. US Preventive Services Task Force. Screening for Bacterial Vaginosis in Pregnant Persons to Prevent Preterm Delivery: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323(13):1286-1292. www.uspreventiveservicestaskforce.org/uspstf/recommendation/bacterial-vaginosis-in-pregnancy-to-prevent-preterm-delivery-screening
  50. US Preventive Services Task Force. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322(5):438-444. www.uspreventiveservicestaskforce.org/uspstf/recommendation/pancreatic-cancer-screening
  51. US Preventive Services Task Force. Screening for Testicular Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. Ann Intern Med. 2011;154(7):483-486. www.uspreventiveservicestaskforce.org/uspstf/recommendation/testicular-cancer-screening
  52. US Preventive Services Task Force. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2023;329(6):502-507. www.uspreventiveservicestaskforce.org/uspstf/recommendation/genital-herpes-serologic-screening
  53. US Preventive Services Task Force. Screening for Asymptomatic Bacteriuria in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322(12):1188-1194. www.uspreventiveservicestaskforce.org/uspstf/recommendation/asymptomatic-bacteriuria-in-adults-screening
  54. US Preventive Services Task Force. Screening for Hearing Loss in Older Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(12):1196-1201. www.uspreventiveservicestaskforce.org/uspstf/recommendation/hearing-loss-in-older-adults-screening
  55. US Preventive Services Task Force. Screening for Impaired Visual Acuity in Older Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(21):2123-2128. www.uspreventiveservicestaskforce.org/uspstf/recommendation/impaired-visual-acuity-screening-older-adults
  56. US Preventive Services Task Force. Screening for Cognitive Impairment in Older Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323(8):757-763. www.uspreventiveservicestaskforce.org/uspstf/recommendation/cognitive-impairment-in-older-adults-screening
  57. US Preventive Services Task Force. Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(2):177-183. www.uspreventiveservicestaskforce.org/uspstf/recommendation/peripheral-artery-disease-in-adults-screening-with-the-ankle-brachial-index
  58. US Preventive Services Task Force. Screening for Celiac Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2017;317(12):1252-1257. www.uspreventiveservicestaskforce.org/uspstf/recommendation/celiac-disease-screening
  59. US Preventive Services Task Force. Screening for Primary Open-Angle Glaucoma: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(20):1992-1997. www.uspreventiveservicestaskforce.org/uspstf/recommendation/primary-open-angle-glaucoma-screening
  60. US Preventive Services Task Force. Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(22):2308-2314. www.uspreventiveservicestaskforce.org/uspstf/recommendation/cardiovascular-disease-risk-screening-with-electrocardiography
  61. Moyer VA; US Preventive Services Task Force. Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;155(4):246-251. www.uspreventiveservicestaskforce.org/uspstf/recommendation/bladder-cancer-in-adults-screening
  62. US Preventive Services Task Force. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(15):1290-1295. www.uspreventiveservicestaskforce.org/uspstf/recommendation/skin-cancer-screening
  63. US Preventive Services Task Force. Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(14):1436-1442. www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-d-deficiency-screening
  64. Moyer VA; US Preventive Services Task Force. Screening for oral cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(1):55-60. www.uspreventiveservicestaskforce.org/uspstf/recommendation/oral-cancer-screening
  65. US Preventive Services Task Force. Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;332(11):906-913. www.uspreventiveservicestaskforce.org/uspstf/recommendation/iron-deficiency-anemia-in-pregnant-women-screening-and-supplementation
  66. US Preventive Services Task Force. Screening for Eating Disorders in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(11):1061-1067. www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-eating-disorders-adolescents-adults
  67. US Preventive Services Task Force. Screening for Adolescent Idiopathic Scoliosis: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(2):165-172. www.uspreventiveservicestaskforce.org/uspstf/recommendation/adolescent-idiopathic-scoliosis-screening
  68. Centers for Disease Control and Prevention. Childhood Lead Poisoning Prevention: Clinical Guidance (reviewed August 2025). www.cdc.gov/lead-prevention/hcp/clinical-guidance/index.html
  69. US Preventive Services Task Force. Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;330(3):253-260. www.uspreventiveservicestaskforce.org/uspstf/recommendation/lipid-disorders-in-children-screening
  70. US Preventive Services Task Force. Screening for High Blood Pressure in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;324(18):1878-1883. www.uspreventiveservicestaskforce.org/uspstf/recommendation/blood-pressure-in-children-and-adolescents-hypertension-screening
  71. US Preventive Services Task Force. Screening and Interventions to Prevent Dental Caries in Children Younger Than 5 Years: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(21):2172-2178. www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-dental-caries-in-children-younger-than-age-5-years-screening-and-interventions1
  72. US Preventive Services Task Force. Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(10):963-967. www.uspreventiveservicestaskforce.org/uspstf/recommendation/prediabetes-type2-diabetes-children-adolescents-screening
  73. US Preventive Services Task Force. Interventions for High Body Mass Index in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;332(3):226-232. www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-children-and-adolescents-screening
  74. US Preventive Services Task Force. Screening for Speech and Language Delay and Disorders in Children: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(4):329-334. www.uspreventiveservicestaskforce.org/uspstf/recommendation/speech-and-language-delay-and-disorders-in-children-age-5-and-younger-screening
  75. US Preventive Services Task Force. Screening for Anxiety in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(14):1438-1444. www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-anxiety-children-adolescents
  76. US Preventive Services Task Force. Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(15):1534-1542. www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-children-adolescents

Written and maintained by the uncovermyrisk.com editorial team. We do not have a medical reviewer; every claim links to its primary source above. Last reviewed: 2026-10-30. Spotted an error? See About.